Pirtobrutinib Clinical Trials
27 recruitingDrug
Phase 221Phase 13Phase 32Phase 42Early Phase 11
Showing 1–20 of 27 trials
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743
Recruiting
Phase 2
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Mantle Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute60 enrolled3 locationsNCT06553872
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled129 locationsNCT06973187
Recruiting
Phase 2
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Mantle Cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05529069
Recruiting
Phase 2
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Mantle Cell Lymphoma
M.D. Anderson Cancer Center50 enrolled1 locationNCT06263491
Recruiting
Early Phase 1
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
National Heart, Lung, and Blood Institute (NHLBI)30 enrolled1 locationNCT07428707
Recruiting
Phase 1Phase 2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company279 enrolled36 locationsNCT06876662
Recruiting
Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company787 enrolled38 locationsNCT06876649
Recruiting
Phase 2
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
M.D. Anderson Cancer Center40 enrolled2 locationsNCT06522386
Recruiting
Phase 2
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Leukemia
M.D. Anderson Cancer Center60 enrolled1 locationNCT05536349
Recruiting
Phase 1
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin12 enrolled1 locationNCT05990465
Recruiting
Phase 2
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Kerry Rogers30 enrolled1 locationNCT06466122
Recruiting
Phase 2
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Phase 2
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Inhye Ahn60 enrolled4 locationsNCT06333262
Recruiting
Phase 2
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Chronic Lymphocytic LeukemiaRichter's Transformation
Christine Ryan70 enrolled5 locationsNCT06043674
Recruiting
Phase 1Phase 2
Mosunetuzumab for CLL MRD Clearance
Chronic Lymphocytic LeukemiaLymphomaLeukemia+1 more
Inhye Ahn40 enrolled2 locationsNCT07052695
Recruiting
Phase 2
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
DLBCL - Diffuse Large B Cell Lymphoma
The First Affiliated Hospital of Soochow University29 enrolled1 locationNCT07255963
Recruiting
Phase 2
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Marginal Zone Lymphoma
University of Utah23 enrolled2 locationsNCT06390956